Role of multimodality therapy in cIIIA-N2 non-small cell lung cancer: perspective.

ABSTRACT: A number of promising new approaches for both local and systemic control of locally advanced non-small cell lung cancer have been examined in clinical trials, aimed at improving the patient survival. Development of better systemic therapies by adopting newer agents (such as epidermal growth factor receptor-tyrosine kinase inhibitors and immune checkpoint inhibitors) from advanced non-small cell lung cancer is mandatory. As for radiotherapy, adaptive radiotherapy and proton therapy are under investigation after the RTOG 0617 trial unexpectedly failed to show the efficacy of high-dose radiotherapy for Stage III disease. To date, no Phase III trial has clearly shown the benefit of adding surgery as a part of multimodality therapy for locally advanced non-small cell lung cancer. Such poor prog

SUBMITTER: Horinouchi H 

PROVIDER: S-EPMC5144660 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature